21
May
2026
21
May
2026
Dermal filler brand Teoxane has announced the UK launch of its highly anticipated new evidence-based injection protocol, babyGLOW™ by Teoxane, following its official debut at IMCAS World Congress 2026 in Paris.
Developed by a collective of more than 15 international aesthetic medicine experts — including Glasgow-based practitioner Dr Kieren Bong — the new technique is designed to enhance skin radiance, hydration and texture while preserving natural facial features.
Inspired by contouring and highlighting techniques commonly used in makeup artistry, babyGLOW™ by Teoxane introduces a standardised, anatomy-based protocol intended to help practitioners deliver consistent, reproducible and safe results across a broad range of patients.
According to Teoxane, the protocol has been designed to support healthcare professionals with a simplified injection technique using carefully selected subdermal injection points.
The treatment uses eight targeted facial injection points to optimise product diffusion and light reflection across the mid-face, helping to create a fresher, brighter and more rested appearance.
The protocol is designed to:
Unlike traditional filler approaches focused on structural enhancement or volume correction, babyGLOW™ aims to improve overall skin quality and skin behaviour over time.
The treatment uses TEOSYAL® Puresense Redensity 1, a non-crosslinked hyaluronic acid formulation containing:
The injectable treatment is characterised by high fluidity, allowing for homogeneous dermal and subdermal distribution and skin redensification.
According to Teoxane, patients can expect:
Speaking about the launch, Joanna Underhill, General Manager for Teoxane UK & Ireland, said the new protocol reflects growing demand for treatments focused on skin quality rather than dramatic transformation.
She commented:
“This contouring glow treatment that elevates skin quality and natural radiance is already loved by patients and trusted by healthcare professionals, and will bring a new, safe, and scientifically supported technique to the UK’s medical aesthetics industry.”
Dr Kieren Bong, Global Teoxane Faculty Member and babyGLOW™ Board Member, also highlighted the industry’s wider movement towards regenerative and skin-focused aesthetic treatments.
He explained:
“babyGLOW™ by Teoxane changes the way we think about skin quality because it shifts the focus away from temporary surface improvement and towards true biological skin remodelling.”
“The future of aesthetics is not simply about changing facial shape, but about improving how the skin behaves, feels and presents over time.”
According to aesthetic practitioner Dr Silvia Caboni, the treatment can be adapted for different age groups and skin concerns.
She explained that younger patients may benefit from preventative hydration and skin maintenance, while mature patients may experience rejuvenating effects through improvements in skin texture and collagen stimulation.
Dr Caboni added:
“Across all ages, patients are usually pleasantly surprised by the immediate glow and the visible improvement in their skin.”
Teoxane also shared interim patient and practitioner satisfaction findings associated with the protocol.
Reported outcomes include:
The launch of babyGLOW™ reflects a wider trend within the aesthetics industry towards more natural-looking outcomes, skin longevity and preventative treatments.
Rather than altering facial structure, the protocol focuses on enhancing hydration, collagen support, tissue repair and overall skin health — aligning with the growing “less is more” philosophy currently shaping modern aesthetic medicine.
Further information about babyGLOW™ by Teoxane can be found via Teoxane Official Website.
Read it? Loved it? Want to share it?
